Michael Thompson: Just to kind of summarize drugs, in some ways we’re in a renaissance period of drugs. We’ve had more discovery in the past decade, and a lot of those drugs have made a huge difference in people’s lives. We should appreciate that and support that. In many instances, there’s a medical offset, and in some instances there’s not. But in any event, those are very important.
I think the issue, from a value-based marketplace, is whether we are being priced fairly, right? Are they being used appropriately, right? And are we getting the outcomes that were advertised, right? I think that’s where the value-based discussion goes from here. I think it’s still to be written. There’s some concern that our intermediaries continue to be motivated by a model that’s gotten outdated. It was a market-share model based on rebates that ultimately evolved into a rebate model, right? We need to fix that, but I don’t think that’s going to be enough. That’s part of the solution, but it’s not the only part of the solution. This is still very much an evolving area, but I think it’s an area that’s on everybody’s radar and we need to stay focused on it.
Well, thank you all for participating in this. This has been fascinating and very engaging. Before we end this discussion, I’d like to open the floor and ask each of you to provide some final thoughts. Dr. Crighton?
Andrew Crighton, MD: I think the No. 1 thing is, it’s a complicated issue that is not going to be easy to solve. But if we keep the patient in mind, and outcomes that improve their lives, we can get to where we need to be. We may have small successes as we go along, but we better celebrate those. We have to be moving in the right direction, or we’re going to be really far behind.
Michael Thompson: Great. Pat?
Patricia Haines: I agree. I think we use the term patient-centered a lot now. We didn’t earlier. So that is a step in the right direction, but there are a lot of smart people who care about this. We have an opportunity because there’s so much focus on it today. It’s different. I’ve been in this business a long time, and it’s different. I think the conversation will get raised through the next election cycle, and I’d love for it to be solved by people who are as invested in it as the 4 of us are. And so we should keep these dialogues going.
Michael Thompson: Yup. Bruce?
Bruce Sherman, MD: A couple of thoughts. I think that the current system as it stands is absolutely unsustainable from a cost standpoint—where we are with healthcare spending as a percentage of GDP [gross domestic product]. We need disruptive solutions. While I appreciate the value of incremental change, I think we have to perhaps learn from our past successes. I continue to think that primary care is an important and vital focus that we need to really increase our attention to, ensuring that it is an effective solution in the marketplace.
Michael Thompson: Yeah. So not being afraid to disrupt, focus on value, and working collectively and collaboratively to move it forward.
I want to thank you all for your contributions to this discussion. On behalf of our panel, we thank you for joining us. We hope you found this AJMC® [The American Journal of Managed Care®] discussion to be useful and informative. Thank you.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Panel Addresses Minority Physician Shortage, Maternal Health at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More